Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04921410 · ClinicalTrials.gov registry record · NA
AI Driven Biofeedback Wearable
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT04921410: Completed NA study, sponsored by Mayo Clinic.
NCT04921410 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04921410, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to conduct a comprehensive clinical and biomechanical screening of high school, collegiate-level, recreational, and Olympic/professional-level athletes with the goal of identifying individual functional and performance deficits that lead to future injury.
Primary Outcome
Lower limb kinetics and kinematics will be calculated with inverse dynamics from 3D motion capture.
Interventions
- DEVICE Biofeedback Knee Sleeve
- DEVICE Sham Biofeedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-07-20 |
| Est. Completion | 2021-07-20 |
| Phase | NA |
What the finished NCT04921410 record still lists
NCT04921410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Biofeedback Knee Sleeve is the first listed.
NCT04921410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04921410 about?
NCT04921410 is a clinical study titled "AI Driven Biofeedback Wearable". The purpose of this study is to conduct a comprehensive clinical and biomechanical screening of high school, collegiate-level, recreational, and Olympic/professional-level athletes with the goal of identifying individual functional and performance deficits that lead to future injury.
What is the current status of trial NCT04921410?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2021-07-20. Estimated completion is 2021-07-20.
What interventions are being tested in trial NCT04921410?
The interventions under investigation include: Biofeedback Knee Sleeve (DEVICE), Sham Biofeedback (DEVICE).
Who is sponsoring clinical trial NCT04921410?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04921410's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI